Document is current

Article History

Accepted: 26 January 2023

First Online: 14 February 2023

Declarations

:

: This research was funded by Incyte Corporation and, in part, through the NIH/NCI Cancer Center Support Grant P30 CA008748 (JJH).

: James J. Harding: Consulting or advisory role for Adaptimmune, Bristol Myers Squibb, CytomX, Eisai, Eli Lilly & Company, Exelixis, Imvax, Merck, Zymeworks; and research funding from Boehringer Ingelheim (Inst), Bristol Myers Squibb (Inst), Calithera Biosciences (Inst), Debiopharm (Inst), Eli Lilly & Company (Inst), Incyte Corporation (Inst), Novartis (Inst), Pfizer (Inst), Polaris Group (Inst), Yiviva (Inst), and Zymeworks (Inst). Christiane Jungels: Travel, accommodations, and expenses from Ipsen, PharmaMar. Jean-Pascal Machiels: Consulting or advisory role for ALX Oncology, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CUE Biopharma, Debiopharm, Incyte Corporation, Innate Pharma, Janssen, Merck Serono, Merck Sharp & Dohme, Nanobiotix, Novartis, Pfizer, Roche; research funding from Bayer, Janssen, Novartis, Sanofi; and travel, accommodations, and expenses from Amgen, Bristol Myers Squibb, Merck Sharp & Dohme, and Pfizer. David C. Smith: Research funding from Agensys (Inst), Atterocor (Inst), Bayer (Inst), Boston Biomedical (Inst), Bristol Myers Squibb/Medarex (Inst), Celgene (Inst), Eli Lilly & Company (Inst), ESSA (Inst), Exelixis (Inst), Genentech (Inst), ImClone Systems (Inst), Incyte Corporation (Inst), MedImmune (Inst), Medivation/Astellas Pharma (Inst), Millennium Pharmaceuticals (Inst), Novartis (Inst), OncoGenex (Inst), OncoMed Pharmaceuticals (Inst), Regeneron (Inst), SeaGen (Inst), Takeda (Inst), Tekmira Pharmaceuticals (Inst), and Teva Pharmaceuticals (Inst). Chris Walker, Tao Ji, Pin Jiang: Former employees of Incyte Corporation. Ekaterine Asatiani, Xin Li: Employment by, and stock ownership in, Incyte Corporation. Eric Van Cutsem: Consulting or advisory role for Array BioPharma, AstraZeneca, Bayer, Biocartis, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Eli Lilly & Company, GlaxoSmithKline, Halozyme, Incyte Corporation, Merck KGaA, Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche, Servier, Sirtex Medical, and Taiho Pharmaceutical Co., Ltd; and research funding from Amgen (Inst), Bayer (Inst), Boehringer Ingelheim (Inst), Bristol Myers Squibb (Inst), Celgene (Inst), Eli Lilly & Company (Inst), Ipsen (Inst), Merck (Inst), Merck KGaA (Inst), Novartis (Inst), Roche (Inst), and Servier (Inst). Ghassan K. Abou-Alfa: Research grants from Arcus, AstraZeneca, BioNtech, Bristol Myers Squibb, Celgene, Flatiron Health, Genentech/Roche, Genoscience Pharma, Incyte Corporation, Polaris Group, Puma Biotechnology, QED Therapeutics, Silenseed, Yiviva; and consultancy with Adicet Bio, Alnylam Pharmaceuticals, AstraZeneca, Autem Therapeutics, BeiGene, Berry Genomics, Boehringer Ingelheim, Celgene, Cend Therapeutics, CytomX, Eisai, Eli Lilly & Company, Exelixis, Flatiron Health, Genentech/Roche, Genoscience Pharma, Helios Pharmaceuticals, Helsinn Group, Incyte Corporation, Ipsen, Merck, Nerviano Medical Sciences, NewBridge Pharmaceuticals, Novartis, QED Therapeutics, Redhill, Rafael Pharmaceuticals, Servier, Silenseed, Sobi, Vector Pharma, and Yiviva.

: Incyte Corporation (Wilmington, DE, USA) is committed to data sharing that advances science and medicine while protecting patient privacy. Qualified external scientific researchers may request anonymized datasets owned by Incyte for the purpose of conducting legitimate scientific research. Researchers may request anonymized datasets from any interventional study (except phase I studies) for which the product and indication have been approved on or after 1 January 2020 in at least one major market (e.g., United States, European Union, Japan). Data will be available for request after the primary publication or 2 years after the study has ended. Information on Incyte’s clinical trial data sharing policy and instructions for submitting clinical trial data requests are available at: .

: The study, registered under ClinicalTrials.gov (NCT03144661), was performed in accordance with the International Conference for Harmonization Good Clinical Practice guidelines, the Declaration of Helsinki, and applicable local regulations with approval from institutional review boards. The study protocol was reviewed and approved by the respective institutional review boards of the participating institutions (Online Supplementary Table 1).

: Written informed consent was obtained for all patients before performing study-related procedures.

: Not applicable.

: Not applicable.

: All authors were responsible for data collection, data integrity and analyses, and data interpretation, and reviewed and edited the manuscript. The corresponding author wrote the initial draft manuscript, had full access to all study data, and had final responsibility for the decision to submit for publication.